75 related articles for article (PubMed ID: 10420905)
1. [Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction].
Koch JA; Sketch M; Brinker J; Bernink PJ
Rofo; 1999 Jun; 170(6):557-63. PubMed ID: 10420905
[TBL] [Abstract][Full Text] [Related]
2. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group.
Koch JA; Plum J; Grabensee B; Mödder U
Nephrol Dial Transplant; 2000 Jan; 15(1):43-9. PubMed ID: 10607766
[TBL] [Abstract][Full Text] [Related]
4. [Prevention of acute renal failure in suprarenal aortic surgery. Results of a pilot study].
Torsello G; Kutkuhn B; Kniemeyer H; Sandmann W
Zentralbl Chir; 1993; 118(7):390-4. PubMed ID: 8372519
[TBL] [Abstract][Full Text] [Related]
5. [Re: Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction. Fortsch Röntgenstr 170 (1999) 557-563].
Fröhlich J
Rofo; 1999 Oct; 171(4):342-3. PubMed ID: 10598177
[No Abstract] [Full Text] [Related]
6. [Effect of prostaglandin E1 on extravascular lung water in patients with severe heart failure].
Lenz K; Kranz A; Kramer L; Buder R; Schollmayer E
Wien Klin Wochenschr; 1996; 108(16):505-9. PubMed ID: 8967094
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
8. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.
Sketch MH; Whelton A; Schollmayer E; Koch JA; Bernink PJ; Woltering F; Brinker J;
Am J Ther; 2001; 8(3):155-62. PubMed ID: 11344383
[TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
[TBL] [Abstract][Full Text] [Related]
10. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency.
Hans SS; Hans BA; Dhillon R; Dmuchowski C; Glover J
Am Surg; 1998 May; 64(5):432-6. PubMed ID: 9585778
[TBL] [Abstract][Full Text] [Related]
11. Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients.
Manasia AR; Leibowitz AB; Miller CM; Silverstein JH; Schwartz M; Delgiudice R; Vallabhajosula S; Oropello JM; Benjamin E
J Am Coll Surg; 1996 Apr; 182(4):347-52. PubMed ID: 8605558
[TBL] [Abstract][Full Text] [Related]
12. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Spargias K; Adreanides E; Demerouti E; Gkouziouta A; Manginas A; Pavlides G; Voudris V; Cokkinos DV
Circulation; 2009 Nov; 120(18):1793-9. PubMed ID: 19841299
[TBL] [Abstract][Full Text] [Related]
13. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome.
Vincent JL; Brase R; Santman F; Suter PM; McLuckie A; Dhainaut JF; Park Y; Karmel J
Intensive Care Med; 2001 Oct; 27(10):1578-83. PubMed ID: 11685297
[TBL] [Abstract][Full Text] [Related]
14. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
[TBL] [Abstract][Full Text] [Related]
15. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study.
Chen HH; Sundt TM; Cook DJ; Heublein DM; Burnett JC
Circulation; 2007 Sep; 116(11 Suppl):I134-8. PubMed ID: 17846293
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
Seyon RA; Jensen LA; Ferguson IA; Williams RG
Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
[TBL] [Abstract][Full Text] [Related]
17. Contrast-induced nephrotoxicity in renal allograft recipients.
Ahuja TS; Niaz N; Agraharkar M
Clin Nephrol; 2000 Jul; 54(1):11-4. PubMed ID: 10939751
[TBL] [Abstract][Full Text] [Related]
18. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Xinwei J; Xianghua F; Jing Z; Xinshun G; Ling X; Weize F; Guozhen H; Yunfa J; Weili W; Shiqiang L
Am J Cardiol; 2009 Aug; 104(4):519-24. PubMed ID: 19660605
[TBL] [Abstract][Full Text] [Related]
19. [Contrast media-induced kidney failure cannot be prevented by hemodialysis].
Berger ED; Bader BD; Bösker J; Risler T; Erley CM
Dtsch Med Wochenschr; 2001 Feb; 126(7):162-6. PubMed ID: 11236522
[TBL] [Abstract][Full Text] [Related]
20. Post-coronarography application of continuous veno-venous hemofiltration in the prevention of contrast nephropathy in patients with complex multisystem deficiency.
La Manna G; Pancaldi L; Dalmastri V; Cuna V; Capecchi A; Comai G; Persici E; Bacchi G; Cianciolo G; Lombardi A; Marrozzini C; Colì L; Stefoni S
In Vivo; 2008; 22(1):123-9. PubMed ID: 18396794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
